FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2089668045> ?p ?o ?g. }

• W2089668045 endingPage "137" @default.
• W2089668045 startingPage "126" @default.
• W2089668045 abstract "The mammalian target of rapamycin (mTOR), a downstream effector of the phosphatidylinositol 3-kinase (PI3K)/Akt (protein kinase B) signaling pathway that mediates cell survival and proliferation, is a prime strategic target for anticancer therapeutic development. By targeting mTOR, the immunosuppressant and antiproliferative agent rapamycin inhibits signals required for cell cycle progression, cell growth, and proliferation. Both rapamycin and novel rapamycin analogues with more favorable pharmaceutical properties, such as CCI-779, RAD 001, and AP23573, are highly specific inhibitors of mTOR. In essence, these agents gain function by binding to the immunophilin FK506 binding protein 12 and the resultant complex inhibits the activity of mTOR. Because mTOR activates both the 40S ribosomal protein S6 kinase (p70s6k) and the eukaryotic initiation factor 4E-binding protein-1, rapamycin-like compounds block the actions of these downstream signaling elements, which results in cell cycle arrest in the G1 phase. Rapamycin and its analogues also prevent cyclin-dependent kinase (CDK) activation, inhibit retinoblastoma protein phosphorylation, and accelerate the turnover of cyclin D1, leading to a deficiency of active CDK4/cyclin D1 complexes, all of which potentially contribute to the prominent inhibitory effects of rapamycin at the G1/S boundary of the cell cycle. Rapamycin and rapamycin analogues have demonstrated impressive growth-inhibitory effects against a broad range of human cancers, including breast cancer, in preclinical and early clinical evaluations. In breast cancer cells, PI3K/Akt and mTOR pathways seem to be critical for the proliferative responses mediated by the epidermal growth factor receptor, the insulin growth factor receptor, and the estrogen receptor. Furthermore, these pathways may be constitutively activated in cancers with many types of aberrations, including those with loss of PTEN suppressor gene function. Therefore, the development of inhibitors of mTOR and related pathways is a rational therapeutic strategy for breast and other malignancies that possess a wide range of aberrant molecular constituents. This review will summarize the principal mechanisms of action of rapamycin and rapamycin derivatives, as well as the potential utility of these agents as anticancer therapeutic agents with an emphasis on breast cancer. The preliminary results of early clinical evaluations with rapamycin analogues and the unique developmental challenges that lie ahead will also be discussed." @default.
• W2089668045 created "2016-06-24" @default.
• W2089668045 creator A5000961519 @default.
• W2089668045 creator A5011905014 @default.
• W2089668045 creator A5028833538 @default.
• W2089668045 date "2003-06-01" @default.
• W2089668045 modified "2023-10-16" @default.
• W2089668045 title "Mammalian Target of Rapamycin: A New Molecular Target for Breast Cancer" @default.
• W2089668045 cites W1486193010 @default.
• W2089668045 cites W1526859945 @default.
• W2089668045 cites W1568605582 @default.
• W2089668045 cites W1661647511 @default.
• W2089668045 cites W169736967 @default.
• W2089668045 cites W1864862165 @default.
• W2089668045 cites W1912098244 @default.
• W2089668045 cites W1949632792 @default.
• W2089668045 cites W1966275499 @default.
• W2089668045 cites W1969442037 @default.
• W2089668045 cites W1971727526 @default.
• W2089668045 cites W1979400471 @default.
• W2089668045 cites W1979819215 @default.
• W2089668045 cites W1979909416 @default.
• W2089668045 cites W1980720313 @default.
• W2089668045 cites W1983061888 @default.
• W2089668045 cites W1983566498 @default.
• W2089668045 cites W1985046929 @default.
• W2089668045 cites W1986235662 @default.
• W2089668045 cites W1987105275 @default.
• W2089668045 cites W1987597886 @default.
• W2089668045 cites W1990098395 @default.
• W2089668045 cites W1993836723 @default.
• W2089668045 cites W1997006452 @default.
• W2089668045 cites W1998762942 @default.
• W2089668045 cites W1999447199 @default.
• W2089668045 cites W2001135952 @default.
• W2089668045 cites W2001413092 @default.
• W2089668045 cites W2001881651 @default.
• W2089668045 cites W2003347015 @default.
• W2089668045 cites W2005623180 @default.
• W2089668045 cites W2006559495 @default.
• W2089668045 cites W2006874274 @default.
• W2089668045 cites W2015277956 @default.
• W2089668045 cites W2016618027 @default.
• W2089668045 cites W2017292900 @default.
• W2089668045 cites W2018244552 @default.
• W2089668045 cites W2020425601 @default.
• W2089668045 cites W2023012828 @default.
• W2089668045 cites W2023584100 @default.
• W2089668045 cites W2024842574 @default.
• W2089668045 cites W2026389696 @default.
• W2089668045 cites W2027953312 @default.
• W2089668045 cites W2029003444 @default.
• W2089668045 cites W2031264891 @default.
• W2089668045 cites W2034269086 @default.
• W2089668045 cites W2035016947 @default.
• W2089668045 cites W2037532701 @default.
• W2089668045 cites W2040405621 @default.
• W2089668045 cites W2044655112 @default.
• W2089668045 cites W2046867705 @default.
• W2089668045 cites W2047174875 @default.
• W2089668045 cites W2048059265 @default.
• W2089668045 cites W2049961020 @default.
• W2089668045 cites W2057080108 @default.
• W2089668045 cites W2057106513 @default.
• W2089668045 cites W2059221693 @default.
• W2089668045 cites W2062083574 @default.
• W2089668045 cites W2063013559 @default.
• W2089668045 cites W2068345721 @default.
• W2089668045 cites W2068413127 @default.
• W2089668045 cites W2069105509 @default.
• W2089668045 cites W2073586734 @default.
• W2089668045 cites W2076024460 @default.
• W2089668045 cites W2077673188 @default.
• W2089668045 cites W2078049733 @default.
• W2089668045 cites W2084324795 @default.
• W2089668045 cites W2087258136 @default.
• W2089668045 cites W2088947878 @default.
• W2089668045 cites W2089531514 @default.
• W2089668045 cites W2090407808 @default.
• W2089668045 cites W2096671082 @default.
• W2089668045 cites W2102648794 @default.
• W2089668045 cites W2109366969 @default.
• W2089668045 cites W2113280225 @default.
• W2089668045 cites W2114492564 @default.
• W2089668045 cites W2114859236 @default.
• W2089668045 cites W2117350664 @default.
• W2089668045 cites W2120356140 @default.
• W2089668045 cites W2128412799 @default.
• W2089668045 cites W2130773839 @default.
• W2089668045 cites W2131487430 @default.
• W2089668045 cites W2135090837 @default.
• W2089668045 cites W2142506125 @default.
• W2089668045 cites W2146697101 @default.
• W2089668045 cites W2150178760 @default.
• W2089668045 cites W2150233389 @default.
• W2089668045 cites W2150776707 @default.
• W2089668045 cites W2151559596 @default.
• W2089668045 cites W2154995637 @default.

• next